A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.
Roche and Blueprint Medicines have signed a global licensing and collaboration deal worth up to $1.7bn for the latter's pralsetinib, an investigational treatment for RET-altered cancers.
Merck, a leading science and technology company, opened its M Lab Collaboration Centre in Shanghai, the company's largest of nine centers worldwide.
Kymera Therapeutics announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialise first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.
Major drugmaker Pfizer has committed $100m to the new Antimicrobial Resistance (AMR) Action Fund, which will support the development of new antibiotics due to increasing antibiotic-resistant infections.
Reliable Oxygen Measurements Continuous dissolved oxygen (DO) measurement is critical during fermentation and cell culture.
Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, announced it has raised $110 million in a Series B financing.
Goldfinch Bio has raised $100m in a Series B funding round for the discovery and development of precision drugs for the treatment of kidney diseases.
Sanofi Pasteur has signed a fresh deal potentially worth up to $2.32bn with US-based Translate Bio to expand an existing partnership of developing vaccines for infectious diseases by using the latter's messenger RNA technology (mRNA technology).
Frontier Scientific, a world leader in porphyrin chemistry and chemical building blocks for drug discovery and material science research, announced their collaboration with Renibus Therapuetics to develop a therapeutic for Covid-19.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.